Lipanor treatment of atherogenic hyperlipoproteinemia

Aim. The study of the hypolipidemic efficiency, safety and tolerance of cip rofibrate (lipanor) in therapy of atherogenic hyperlipoproteinemia. Materials and methods. The trial included 14 hypertensive postmenopausal fe males, 14 patients with diabetes mellitus type II, 14 males with coronary h eart disease and primary hyperlipoproteinemia (total cholesterol >6.5 mmol/ l, triglycerides <4.5 mmol/l under low-cholesterol diet). Lipanor was given for 12 weeks in a daily single dose 100 mg in the morning. Lipids and othe r biochemical indices were measured in a fasting state after 1 and 3 months of lipanor treatment. Results. After 1 month of lipanor treatment there was a 22-30%, 24-49% decr ease in the level of low-density lipoprotein cholesterol, triglycerides, re spectively. High-density lipoprotein cholesterol increased by 16%. The hypo lipidemic effect of lipanor persisted for 3 months during which triglycerid es continued to fall (up to 38.5%). Lipanor was well tolerated, only one pa tient with diabetes mellitus had hyperactivity of creatine phosphokinase ma nifesting with clinical symptoms (the drug was discontinued). 3 patients de veloped mild side effects. Alkaline phosphatase activity inhibited in all t he groups by 25-41%. Conclusion. Lipanor is a highly effective, safe hypolipidemic drug with goo d tolerance. It can be recommended for correction of atherogenic hyperlipop roteinemia in patients at high risk of atherosclerosis progression.